204 related articles for article (PubMed ID: 34418455)
1. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.
Koren E; Apte A; Jani A; Torchilin VP
J Control Release; 2012 Jun; 160(2):264-73. PubMed ID: 22182771
[TBL] [Abstract][Full Text] [Related]
3. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
4. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
[TBL] [Abstract][Full Text] [Related]
5. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A; Koren E; Koshkaryev A; Torchilin VP
Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
[TBL] [Abstract][Full Text] [Related]
8. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
[TBL] [Abstract][Full Text] [Related]
9. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
[TBL] [Abstract][Full Text] [Related]
10. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
[TBL] [Abstract][Full Text] [Related]
11. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes.
Kale AA; Torchilin VP
J Drug Target; 2007; 15(7-8):538-45. PubMed ID: 17671900
[TBL] [Abstract][Full Text] [Related]
12. "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes.
Kale AA; Torchilin VP
J Liposome Res; 2007; 17(3-4):197-203. PubMed ID: 18027240
[TBL] [Abstract][Full Text] [Related]
13. Optimal Design of Novel Functionalized Nanoconjugates Based on Polymalic Acid for Efficient Tumor Endocytosis with Enhanced Anticancer Activity.
Guo S; Zhou Q; Yang T; Qiao Y; Fan L; Wang C; Wu H
J Biomed Nanotechnol; 2018 Jun; 14(6):1039-1051. PubMed ID: 29843869
[TBL] [Abstract][Full Text] [Related]
14. Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells.
Amin M; Bagheri M; Mansourian M; Jaafari MR; Ten Hagen TL
Int J Nanomedicine; 2018; 13():7441-7455. PubMed ID: 30532532
[TBL] [Abstract][Full Text] [Related]
15. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
16. A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer.
Zhai L; Luo C; Gao H; Du S; Shi J; Wang F
Int J Nanomedicine; 2021; 16():3185-3199. PubMed ID: 34007173
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.
Vakili-Ghartavol R; Mehrabian A; Mirzavi F; Rezayat SM; Mashreghi M; Farhoudi L; Kharrazi S; Sadri K; Jaafari MR
J Pharm Pharmacol; 2022 Sep; 74(9):1307-1319. PubMed ID: 35833585
[TBL] [Abstract][Full Text] [Related]
18. Formulation, characterization and tissue distribution of a novel pH-sensitive long-circulating liposome-based theranostic suitable for molecular imaging and drug delivery.
Duan Y; Wei L; Petryk J; Ruddy TD
Int J Nanomedicine; 2016; 11():5697-5708. PubMed ID: 27843312
[TBL] [Abstract][Full Text] [Related]
19. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.
Kuai R; Yuan W; Qin Y; Chen H; Tang J; Yuan M; Zhang Z; He Q
Mol Pharm; 2010 Oct; 7(5):1816-26. PubMed ID: 20701288
[TBL] [Abstract][Full Text] [Related]
20. Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.
Biswas S; Dodwadkar NS; Sawant RR; Torchilin VP
Bioconjug Chem; 2011 Oct; 22(10):2005-13. PubMed ID: 21870873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
